BACK
Project/Company Name
ACE NanoMed Limited 頂尖納米醫療有限公司
Project Leader
Source of Funding/Programme
TSSSU
Description
ACE NanoMed is a Research and Development company aiming to invent and commercialize first-in-class therapeutics with highly specific targeting effect to Epstein-Barr virus (EBV)-associated malignancies, including nasopharyngeal carcinoma (NPC), gastric cancer, Burkitt’s lymphoma and Hodgkin lymphoma. We strive to implement aptamer-based and mRNA-based innovative drugs (developed by our research team in Chinese University of Hong Kong) into clinical practice for patient treatments. These drugs are designed to target and induce the death of EBV-infected cancer cells, thereby sparing the normal cells in the body safe from the therapy, as well as lessening the side effects endured by the patients.
Project/Company Name
ACE NanoMed Limited 頂尖納米醫療有限公司
Project Leader
Source of Funding/Programme
TSSSU
Description
ACE NanoMed is a Research and Development company aiming to invent and commercialize first-in-class therapeutics with highly specific targeting effect to Epstein-Barr virus (EBV)-associated malignancies, including nasopharyngeal carcinoma (NPC), gastric cancer, Burkitt’s lymphoma and Hodgkin lymphoma. We strive to implement aptamer-based and mRNA-based innovative drugs (developed by our research team in Chinese University of Hong Kong) into clinical practice for patient treatments. These drugs are designed to target and induce the death of EBV-infected cancer cells, thereby sparing the normal cells in the body safe from the therapy, as well as lessening the side effects endured by the patients.
Starting Year
2023
Business Area
Biotech
Nature
TSSSU Company